Drug Profile

exoASO C/EBPB

Alternative Names: exoASO™-C/EBPB; exoASO™-C/EBPβ

Latest Information Update: 17 Nov 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Codiak BioSciences
Class Antineoplastics; Antisense oligonucleotides; Immunotherapies
Mechanism of Action CCAAT enhancer binding protein expression inhibitors; CEBPB protein expression inhibitors; RNA interference

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Colorectal cancer; Gastric cancer; Non-small cell lung cancer

Most Recent Events

10 Nov 2022 Pharmacodynamics data from a preclinical study in Cancer released by Codiak BioSciences
03 Nov 2022 Preclinical trials in Colorectal cancer in USA (IV) before November 2022
03 Nov 2022 Preclinical trials in Gastric cancer in USA (IV) before November 2022

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com